Ginkgo Bioworks Holdings, Inc. (DNA) Covered Calls

Ginkgo Bioworks Holdings, Inc. is a synthetic biology company that treats "biology as a programmable platform." It operates a high-throughput automated "Foundry" to design and engineer custom microorganisms for various industries, including pharmaceuticals, agriculture, and food. By leveraging advanced software and AI-driven automation, the company aims to scale biological engineering similarly to computer programming and semiconductor manufacturing.

You can sell covered calls on Ginkgo Bioworks Holdings, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DNA (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Ginkgo Bioworks Holdings, Inc. (DNA) operates a horizontal platform for cell programming. Its core value proposition is the "Foundry"—a massive, highly automated laboratory in Boston that utilizes robotics and proprietary software to design, build, and test custom microorganisms. These engineered cells are used by customers to produce everything from sustainable food ingredients and fragrances to novel medicines and agricultural biologicals. Ginkgo earns revenue through a combination of upfront research fees and potential "downstream" value in the form of milestone payments, royalties, or equity in the products developed.

In 2026, Ginkgo has transitioned significantly toward a "tools-driven" model, launching Autonomous Labs (RAC systems) that allow customers to bring Ginkgo’s automation in-house. A major pillar of its current strategy is the integration of generative AI; the company recently achieved a 40% improvement in scientific benchmarks using its Catalyst Agent, an AI-reasoning model powered by OpenAI’s GPT-5. Additionally, its Ginkgo Datapoints service provides large-scale biological datasets to pharmaceutical companies to train their own AI models for drug discovery, capitalizing on the "Lab-in-the-loop" trend in biotechnology.

Competitive Landscape

The synthetic biology sector is highly competitive, with Ginkgo facing pressure from both pure-play syn-bio firms and specialized life science tool providers. Its most direct competitor is Twist Bioscience, which dominates the synthetic DNA synthesis market. While Twist focuses on the "writing" of DNA, Ginkgo focuses on the "programming" and testing of entire cells. In the tools and services space, Ginkgo also competes with Pacific Biosciences (PacBio) and Cytek Biosciences for R&D budget allocation.

As Ginkgo expands its biosecurity division, it increasingly vies for government contracts against established defense and health security firms. In the pharmaceutical sector, it competes with contract research organizations (CROs) and in-house R&D departments of "Big Pharma" companies. Ginkgo differentiates itself through its "Codebase"—a massive library of genetic parts and biological data—which allows it to start new projects with a significant data advantage over competitors who are building from scratch.

Strategic Outlook and Innovation

Ginkgo’s strategic focus for 2026 is reaching operational break-even following a period of aggressive scaling. The company is prioritizing high-margin "Tools" revenue, such as its partnership with Google Cloud to build a foundation model for engineering biology. Following a reverse stock split in 2024 to maintain its NYSE listing, management is now focused on the commercialization of its RAC (Reliable Autonomous Cell) systems, which represent a shift from purely providing services to selling the infrastructure of synthetic biology.

Innovation at Ginkgo is currently led by the deployment of GinkgoAI, which automates the experimental design process. By using "Active Learning" loops, the platform can automatically decide which biological experiments to run next based on previous results, significantly reducing the human labor required for complex strain engineering. With major 2026 collaborations in peptide-based agriculture and cell-based bioelectronics, Ginkgo aims to prove that its platform is not just a scientific marvel, but a commercially indispensable utility for the global bioeconomy.

Want more examples? DMRC Covered Calls | DNL Covered Calls